Symphogen Opens US Operations in Princeton, New Jersey - Gilde Healthcare

Symphogen Opens US Operations in Princeton, New Jersey

3. November 2009

-US Subsidiary Supports Expanding Opportunities for Symphogen’s Novel Antibody Pipeline and Discovery and Expression Platforms-

COPENHAGEN, Denmark and PRINCETON, NJ – Symphogen A/S today announced the opening of its United States headquarters in Princeton, New Jersey. Adriann Sax, Symphogen’s recently appointed Chief Business Officer, will head the Company’s US business which will operate as Symphogen, Inc., a wholly-owned subsidiary of Symphogen A/S.

“This is the optimal time to strengthen Symphogen’s global presence as our novel pipeline is advancing into the later-stages of clinical development,”

said Kirsten Drejer, Ph.D., CEO of Symphogen.
Ms. Sax added,

“Antibody therapeutics and technologies continue to drive significant value for the pharmaceutical industry.  New Jersey has long been recognized as good centralized location for bioscience companies with global development programs and multiple worldwide partnerships, so it was an easy decision for Symphogen to base our US business here.  With Symphogen’s growing pipeline and leading antibody discovery and expression technologies, we are excited about the company’s future prospects and hope to capitalize on these opportunities by having broad access to physicians, patients and partners.”

About Symphogen

Symphogen is developing superior antibody therapeutics to help people with serious diseases.  With its proprietary SymplexTM discovery and SympressTM manufacturing platforms, the company captures the diversity and specificity of the natural immune response in rationally designed recombinant antibody compositions.  Symphogen is maturing a diversified pipeline of internal and partnered products across multiple indications including cancer and infectious disease.  Symphogen is a private biopharmaceutical company with more than 70 employees, and its headquarters are based in Copenhagen, Denmark.  www.symphogen.com

Gilde Healthcare company ProVerum Announces Completion of Enrollment for the ProVIDE Clinical Study for BPH and First-use of its New Flexible, Steerable Delivery System

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor's office, today announced completion of enrollment of the ProVIDE pivotal clinical trial to evaluate...
21. März 2024

Gilde Healthcare veräussert RAD-x an ein konsortium aus Swiss Life Asset Managers und Vesper Infrastructure Fund I

Gilde Healthcare´s Private Equity Fund (“Gilde Healthcare”), ein auf das Gesundheitswesen spezialisierter Investor, hat eine bindende Vereinbarung über den Verkauf seiner Mehrheitsbeteiligung an RAD-x an ein Konsortium aus Swiss Life Asset Managers und Vesper Next...
18. März 2024

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V.,...
29. Februar 2024